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+ T-cell count after cART initiation and, more rarely, even in treated patients with a fully suppressed VL [13] . PML is also increasingly seen in HIV-uninfected patients receiving humanized antibody-based immunomodulatory drugs, such as natalizumab for multiple sclerosis [14] and rituximab for various disorders [15] . However, as in the HIV-infected population, PML develops in few patients with profound treatment-related cellular immunosuppression, suggesting that other factors, such as individual susceptibility, play a key role [16, 17] . Interestingly, PML is rarely reported in sub-Saharan Africa, pointing to the existence of protective host genetic factors [16, 17] . Alternative explanations include interactions between JCV and geographically specific HIV-1 clades [18] , circulation of less virulent JCV strains in Africa [7, 19] , competing risks such as tuberculosis, and underdiagnosis or underreporting.
The aims of the current study were to assess the risk of PML in the cART era among HIV-1-infected individuals enrolled in the French Hospital Database on HIV (FHDH-ANRS CO4) and to identify risk factors for PML onset. In particular, we determined whether sub-Saharan African origin was protective. We also assessed the impact of a recent cART initiation
PATIENTS AND METHODS

Study Population
FHDH is a hospital-based, open multicenter cohort in which inclusions have been ongoing since 1989 [20] . It includes data on patients managed in 70 general and university hospitals distributed throughout France. Individuals are eligible if they have documented HIV type 1 or 2 infection and give their written informed consent to participate. Data are collected prospectively by trained research assistants on standardized forms, including demographic characteristics, biological markers such as the CD4 + T-cell count and plasma HIV RNA load, the date and type of AIDS-defining and non-AIDS events, antiretroviral treatment, and date and causes of death. The FHDH project was approved by the French computer watchdog authority (Commission Nationale de l'Informatique et des Libertés) on 27 November 1991 (Journal Officiel, 17 January 1992). For this study, patients were selected were >15 years old and had HIV-1 infection, no past or current history of PML, and 1 baseline CD4 + T-cell count analysis, defined as the first count after 1 January 1997. In addition, patients originating from the Caribbean region and those followed up in French overseas territories were not eligible, because their African/non-African origin was not known. We restricted this analysis to individuals with ≥1 CD4 + T-cell count and 1 VL determination between baseline and PML diagnosis, death, the last follow-up visit, or 31 December 2011, whichever occurred first. PML is usually diagnosed on the basis of JCV polymerase chain reaction (PCR) positivity with cerebrospinal fluid and compatible findings at brain magnetic resonance (MR) imaging.
Gasnault et al [21] have shown elsewhere that cases recorded by the clinicians in the database correspond to true PML.
Statistical Analysis
Demographic characteristics, laboratory values, and cART use were compared at inclusion in the study, that is, at baseline, defined as the date of the first CD4 + T-cell count after 1 January Changes in incidence rates were tested for significance by means of Poisson regression analysis. In addition, the incidence rate for the pre-cART period 1992-1996 was calculated for guidance. First, sub-Saharan African origin was studied as a potential protective factor for PML in univariable and multivariable analyses. We used Cox models to calculate hazard ratios (HRs), adjusted for the period of FHDH inclusion, sex, the HIV transmission group, and age at baseline. HRs were also adjusted for AIDS status, current CD4 + T-cell count, and current VL, considered as time-dependent covariates. Because 65% of the individuals with hepatitis C virus (HCV) coinfection (ie, positive HCV serostatus) were injection drug users (IDUs), we conducted 2 sensitivity analyses to distinguish the influence of IDU status from that of HCV coinfection. First, HCV-coinfected individuals were studied after exclusion of the IDUs. Second, IDUs were studied after exclusion of the coinfected individuals. In a second part of the work, we focused on individuals included in the FHDH after 1 January 1997 and who were antiretroviral therapy naive at baseline, to study cART initiation <6 months before PML onset and avoid a survival bias. cART was defined as a regimen consisting of 2 NRTIs plus 1 PI, 1 NNRTI, or 1 integrase inhibitor; 1 PI plus 1 NNRTI; 2 PIs; or 3 NRTIs. The analysis ignored subsequent treatment changes, including interruptions and cessations. In this analysis, we adjusted for the period of FHDH inclusion, sex, and the HIV transmission group, age, CD4 + T-cell count, and AIDS status at baseline. To avoid time-dependent confounding, this model was not adjusted for current CD4 + T-cell count or current VL. cART initiation ≤6 or >6 months previously, compared with no cART initiation, was considered as a time-dependent covariate. All P values are 2 sided. SAS software was used for all statistical analyses (version 9.4; SAS Institute).
RESULTS
Baseline Characteristics
A total of 97 905 individuals in the FHDH cohort met the inclusion criteria for this study. PML had been diagnosed at FHDH inclusion in 154 of these individuals, who were thus excluded from the analysis. Among the remaining individuals, 92 477 participants had ≥1 CD4 + T-cell count and 1 VL measurement between baseline and the end of follow-up (see Supplementary Material). Table 1 shows the patients' baseline characteristics. One-third of FHDH inclusions took place before 1997. Onethird of participants were men who have sex with men (MSM). Individuals from sub-Saharan African tended to have been enrolled more recently, were more often female, were less frequently coinfected with HCV, and had lower baseline CD4 + T-cell counts than individuals of other origins (Table 1) . Baseline characteristics of patients included in the analysis of the impact of cART initiation are shown in Supplementary Material.
Incidence of PML
During the study period, PML developed in 555 patients, for an overall incidence of 0.80/1000 PYFU (95% confidence interval [CI], .73-.87). As shown in Figure Table 2 shows characteristics of the individuals with PML, both overall and separately for the 51 cases diagnosed before cART initiation, the 57 cases diagnosed within 6 months of cART initiation, and the 447 cases diagnosed >6 months after cART initiation. Sixty-one percent of the patients in whom PML developed during follow-up were enrolled in the FHDH before 1997. Patients from sub-Saharan Africa represented only 9% of the PML group, compared with 15% of the total study population. One-third of individuals with PML during follow-up were IDUs, and one-third were MSM. At PML diagnosis, the median CD4 + T-cell count was 99/µL, and the median VL was 10 120 copies/mL. Forty-eight (9%) of the patients with PML had PML diagnosed after having no FHDH visits for more than a year. PML was diagnosed in earlier periods among patients with PML developing after a recent cART initiation than in the other 2 groups. They had a lower median VL at PML diagnosis (1019 copies/mL; interquartile range [IQR], 73-15 700 copies/mL). Their CD4 + T-cell count and VL at cART initiation, respectively, were 104/µL (IQR, 30-195/µL) and 108 321 copies/mL (5725-496 634). In this subgroup, the median interval between cART initiation and PML diagnosis was 76 days (95% CI, 45-122 days).
Risk Factors for PML
Of note, the risk of PML was almost twice as high for those included in the FHDH before 1997 as for those included later (HR, 1.94; 95% CI, 1.63-2.31). As shown in the lower the risk of PML. VLs >500 copies/mL were associated with a higher risk of PML
Risk of PML After cART Initiation
In the analysis studying the impact of cART initiation (Figure 2 ), the risk of PML was higher in patients with cART initiation ≤6 months previously than in those with no cART exposure (HR, 7.66; 95% CI, 4.03-14.58) in univariable analysis. The risk was higher in those with cART initiation >6 months previously than in those with no cART exposure (HR, 2.14; 95% CI, 1.22-3.74). In multivariable analysis, the risk remained far higher in patients with recent cART initiation than in those with no cART exposure (HR, 4.91; 95% CI, 2.42-9.95). However, cART initiation >6 months previously was no longer associated with the risk of PML after adjustment (HR, 0.87; 95% CI, .46-1.63).
DISCUSSION
This large study of 92 477 patients, including 555 with PML shows that the incidence of PML in the FHDH fell by 57% over a 15-year period during the cART era. After taking potential confounders into account, we found that sub-Saharan African origin had no protective effect on PML. In contrast, cART initiation <6 months previously was associated with an increased risk of PML. IDUs were also at an increased risk of PML, as were HCV-coinfected individuals. These 2 risk factors were not confounded, as shown by the 2 sensitivity analyses. Unsurprisingly, whether after or before cART, most PML occurred in individuals with uncontrolled VLs and low CD4 + T-cell counts. This is the largest study of PML among HIV-infected individuals, with 695 000 person-years of prospective follow-up of a population covering all HIV transmission groups. This study has several limitations, however. First, we had no direct access to JCV PCR and brain MR imaging results in the database, but it should be noted that a FHDH database audit endorsed the accuracy of PML diagnoses [21] . Second, the possibility cannot be excluded that HCV serostatus would be a surrogate for underreporting IDU status.
The incidence of PML was 0.80/1000 PYFU (95% CI, .73-.87) in the cART era period 1997-2011 compared with 5.0/1000 PYFU (4.6-5.4) in the pre-cART period 1992-1996, which perfectly illustrates the impact of cART advent. In the period spanning 1997 to 2007, the incidence of PML was 0.6/1000 PYFU (95% CI, .4-1.0) in the Swiss cohort study [12] , 1.4/1000 PYFU (.9-1.9) in the Danish cohort study [22] , and 0.9/1000 PYFU (.8-1.0) in our study. The incidence in the most recent period of our study (2009-2011) was 0.49/1000 PYFU (95% CI, .37-.61), corresponding to a decline of 57% compared with the period 1997-2000. This decrease is probably due at least in part to earlier cART initiation and the use of more effective and simpler cART regimens. Interestingly, this latest incidence rate is lower than that reported among natalizumab-treated patients with multiple sclerosis [14] .
Individuals of sub-Saharan African origin were not protected from PML after adjustment for the HIV transmission group and period of FHDH inclusion. Thus, any genetic protection would be small at best (20% risk reduction). The low reported incidence of PML in sub-Saharan African cohorts could be due to competing risks for death. Lack of availability of PCR to detect JCV and of MR imaging may explain underreporting in some sub-Saharan African countries. This underlines the need to reduce the geographic inequalities in the management of HIVassociated opportunistic CNS infections. Recent cART initiation was associated with an increased risk of PML and accounted for 10% of incident cases. Such individuals in whom PML developed after a recent cART initiation had demographic characteristics similar to those others with PML. Their CD4 + T-cell counts at cART initiation were low (median, 104/µL), and their VLs was relatively high (median, 108 321 copies/mL).
The median interval between cART initiation and PML onset was 76 days (range, 4-175 days), close to the median of 85 days (21-390 days) observed in a study of 13 patients with PML after cART initiation [23] . The standard consideration is that replication competent JCV enters the brain at the onset of PML and causes disease [5] [6] [7] . The temporal link between cART initiation and PML onset suggests that cART uncovers preclinical PML through immune reconstitution. This hypothesis is in line with what we learned from natalizumab-treated patients with multiple sclerosis [24] . PML in these individuals can have a long presymptomatic course while still being clearly detectable with MR imaging. We found a particularly high risk of PML among IDUs, as already noted in the Swiss cohort [12] . Drug toxicity could account for this increased risk. Indeed, opioids could favor PML onset through their suppressive effects on lymphocyte and monocyte function [25] . Findings of neuropathological studies suggest that HIV encephalitis is more frequent in opioid users than in MSM with comparable CD4 + T-cell counts [26] . The FHDH database contains no information on current injection drug or cocaine use. It would have been interesting to study the impact of cocaine, which undermines the blood-brain barrier and enhances cell migration to the brain from blood vessels [22] . In synergy with HIV, this could facilitate the passage of B lymphocytes, the JCV "Trojan horse" vector cell, into the brain. In addition, injection drug use might be a behavioral risk factor for JCV transmission. Ingestion of infected water and food are major modes of JCV transmission [27] [28] [29] , but the intravenous route might also play a noteworthy role. It would be interesting to study JCV seroprevalence in the IDU population. Differences in adherence to cART are unlikely to explain the observed link between IDU and PML, because the analysis was adjusted for the current CD4 + T-cell count and VL. In addition, multivariable analyses in another study have shown that prolonged HIV suppression is as frequent among IDUs in care as in other transmission groups [30] . Our sensitivity analysis excluding IDUs showed that HCVcoinfected individuals were at a particularly high risk of PML. To our knowledge, the potential link between PML onset and HCV, a neurotropic virus [31] , has not previously been studied. HCV belongs to the Flaviviridae family, which includes several wellknown neurotropic viruses, such as yellow fever, dengue, and tickborne encephalitis viruses. The possible impact of HCV infection on cognitive performance is controversial, but HCV seems to be an occasional cause of various CNS disorders [32] [33] [34] .
Unsurprisingly, most of the individuals with >6 months of therapy in whom PML developed had treatment failure with marked past and current immunodeficiency and inadequate HIV VL control. Adherence to cART was probably the main issue in these individuals. PML onset seems to be favored by HIV replication, independently of the CD4 + T-cell count, possibly through HIV Tat protein-mediated activation of JCV replication [35] .
In conclusion, over a 15-year period in the cART era, we found that the incidence of PML fell by more than half in the FHDH. Recent cART initiation was associated with a transient increase in the risk of PML diagnosis, probably by revealing preexisting lesions. Sub-Saharan African origin did not seem to protect patients from PML. Interestingly, the risk of PML was particularly high among IDUs and HCV-coinfected individuals. Further studies are needed to explore the possible link between current drug use and PML onset, the seroprevalence of JCV among IDUs, and the role of neurotropic viruses such as HCV in PML onset.
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Supplementary materials are available at Clinical Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted Figure 2 . Risk factors for progressive multifocal leukoencephalopathy among individuals who were antiretroviral therapy naive at baseline. Results for the time-dependent covariate combination antiretroviral therapy (cART) initiation ≤6 or >6 months previously, compared with no cART initiation (ie, the reference group). We used Cox models to calculate hazard ratios adjusted for the period of inclusion in the French Hospital Database on HIV cohort, sex, the human immunodeficiency virus transmission group, age, CD4 + T-cell count, and AIDS status at baseline in this multivariable analysis. Hazard ratios are shown with 95% confidence intervals.
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